HPV阳性口咽癌治疗降阶研究:DE-ESCALATE与RTOG 1016后的头颈肿瘤国际协作组框架
HPV阳性口咽癌发病率快速上升,患者年轻、预后好,促使治疗降阶概念流行。但首批3项随机降阶试验显示,省略或替换顺铂会导致生存受损。头颈肿瘤国际协作组据此发布框架与指导,建议降阶方案先在II期研究中评估,获得高级别证据前不应进入临床实践,并应评估伤害最小化技术作为替代策略。
要点
- 首批3项随机降阶试验显示省略或替换顺铂导致生存受损。
- 降阶方案应在II期研究中评估,等待结果后再决定是否进入III期。
- 高级别证据前不应将降阶方案用于临床实践。
核心结论
- HPV阳性口咽癌的降阶治疗应在II期研究中评估,获得结果前不应推进至III期研究。
- 在获得高级别证据前,不应将降阶方案实施于临床实践。
- 应评估伤害最小化技术作为降阶治疗的替代策略。
研究设计与样本
- 头颈肿瘤国际协作组基于文献综述与首批3项随机降阶试验结果发布框架与指导。
主要发现
- 首批3项随机降阶试验显示,省略或替换顺铂导致生存明显受损。
临床怎么用
- 降阶方案仅应在II期研究框架内开展,等待结果后再决定是否进入III期。
- 在高级别证据可用前,不应将降阶方案用于常规临床实践。
- 可评估伤害最小化技术作为降阶治疗的替代策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is increasing rapidly. The younger age, significantly improved prognosis, and relative morbidity of the standard-of-care cisplatin and radiotherapy in this population have led to the popularization of the concept of treatment de-escalation. The recent results of the first 3 randomized de-escalation trials, however, have shown a clear detriment in survival when cisplatin is omitted or substituted. In view of these results, the Head and Neck Cancer International Group identified the need to issue guidance regarding future de-escalation studies for patients with HPV-positive head and neck cancer to avoid the possibility of patients being harmed. We review the current state of the literature regarding HPV de-escalation trials and present a framework and guidance on future and existing clinical trials for treatment de-escalation of HPV-positive OPC. De-escalation paradigms of HPV-positive OPC should be evaluated in phase II studies, and results should be awaited before proceeding to phase III studies. Implementation into clinical practice before high-level evidence is available should not be undertaken in this context. Finally, harm-minimization techniques should also be evaluated as an alternative to de-escalation of treatment in these patient groups.
引用
- Mehanna H, Rischin D, Wong SJ, et al. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. J Clin Oncol. 2020. PMID: 32496903. doi:10.1200/JCO.20.00056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。